Skip to Content
Stanford Medicine Dermatology

Stanford Medicine

Explore Stanford Medicine

  • Health Care
    • Find a doctor

    • Adult-care doctor
    • Pediatrician or pediatric specialist
    • Obstetrician
    • Clinics & Services

    • Adult care
    • Pediatric care
    • Obstetrics
    • Clinical trials
    • Locations

    • Stanford Health Care
    • Stanford Children's Health
    • Emergency Department
    • Dial 911 in the event of a medical emergency

    Explore Health Care

    Learn how we are healing patients through science & compassion

    Back
  • Research
    • Basic science departments
    • Clinical science departments
    • Institutes
    • Research centers
    • See full directory
    • Research Resources

    • Research administration
    • Academic profiles
    • Clinical trials
    • Funding opportunities
    • See all
    • Professional Training

    • Postdoctoral scholars
    • Clinical research fellows

    Research News

    Neuroscientist Michelle Monje awarded MacArthur 'genius grant'

    Neuroscientist Michelle Monje awarded MacArthur 'genius grant'

    Explore Research

    Learn how we are fueling innovation

    Back
  • Education
    • MD program
    • PA Programs
    • PhD programs
    • Masters programs
    • Continuing Medical Education
    • Postdoctoral scholars
    • Residencies & fellowships
    • High School & Undergraduate Programs
    • See all
    • Education Resources

    • Academic profiles
    • School Administration
    • Basic science departments
    • Clinical science departments
    • Alumni services
    • Faculty resources
    • Diversity programs
    • Lane Library
    • Student resources

    Education News

    Alice L. Walton School of Medicine and Stanford Medicine host AI conference on community health

    Alice L. Walton School of Medicine and Stanford Medicine host AI conference on community health

    Explore Education

    Learn how we empower tomorrow's leaders

    Back
  • Give

    Support Stanford Medicine

    • Support teaching, research, and patient care.

    • Ways to give
    • Why giving matters
    • Make a gift online

    Support Children's Health

    • Support Lucile Packard Children's Hospital Stanford and child and maternal health

    • Ways to give
    • How your gift helps
    • Make an online gift
    Back
  • About
    • About us
    • News
    • Contacts
    • Maps & directions
    • Leadership
    • Vision
    • Diversity
    • Global health
    • Community engagement
    • Events
    • How you can help

    Stanford School of Medicine

    Stanford Health Care

    Stanford Children's Health

    Back
  • Site Search
  • Faculty

    Faculty

    • All Affiliated Faculty
    • Open Faculty Positions
  • Education

    Education

    • Residency

      Residency

      • Message from Program Directors
      • Residency Program Leadership
      • Research and Elective Opportunities
      • Subspecialties
      • Curriculum
      • Residents
      • Resident Life
      • Resident Wellness
      • Application Process
      • Resources
      • Global Health
      • Clinical Sites
      • Salary & Benefits
    • Medical Students
    • Fellowship

      Fellowship

      • Post-Doctoral Research Fellowship
      • Peds Research Fellowship
      • Melanoma-focused Research Fellowship
    • Visiting Rotations & Observerships
    • Grand Rounds

      Grand Rounds

      • Information for Patients
      • Information for Doctors
      • Directions
    • Rodan + Fields Lecture
    • COVID as a Catalyst Webinar
    • Marvin Karasek Lecture
  • Research

    Research

    • Stanford EB Research

      Stanford EB Research

      • Current Studies

        Current Studies

        • Genetic Testing for DEB
        • Serlopitant for Itch in EB
        • Characteristics of RDEB Patients
        • EB 101 for RDEB
        • Intravenous C7 for RDEB
        • Injected Gene Therapy for RDEB
        • Exon Skipping Therapy
        • EBCRC
        • RDEB Wound Natural History
        • Stanford and UMCG Cannabinoid Survey
        • Drug Repurposing
      • Prior Clinical Studies
      • Pre-Clinical Studies to Date
      • Meet the Clinical Research Team
      • Stanford EB Publications
      • In the Press
    • Clinical Trials
    • Skin Cancer Brochure
    • Epithelial Biology Program
    • Stanford EB Research

      Stanford EB Research

      • Current Studies

        Current Studies

        • Serlopitant for Itch in EB
        • Characteristics of RDEB Patients
        • EB 101 for RDEB
        • Intravenous C7 for RDEB
        • Topical Gene Therapy for RDEB
        • Injected Gene Therapy for RDEB
        • Exon Skipping Therapy
        • EBCRC
        • RDEB Wound Natural History
        • Stanford and UMCG Cannabinoid Survey
        • Drug Repurposing
      • Prior Clinical Studies
      • Pre-Clinical Studies to Date
      • Meet the Clinical Research Team
      • Stanford EB Publications
      • In the Press
    • Stanford Skin Innovation and Interventional Research Group
    • Translational AI in Dermatology (TRAIND)
  • Resources

    Resources

    • Department History
    • Photo Instruction for Video Visits
    • Epithelial Biology Program
    • Genetic Skin Disease Center

      Genetic Skin Disease Center

      • Epidermolysis Bullosa Clinic

        Epidermolysis Bullosa Clinic

        • EB FAQs
        • EB Clinic Visits
        • EB Wound Care Videos
        • EB Resources
        • EB People
      • Our Team
      • Clinic Appointments and Referrals
      • Support Our Research
      • Contact Us
    • In The Spotlight Archive
    • Related Links
    • Clinical Schedules
    • Newsletter
    • Resident On-Call Schedule
  • Patient Care

    Patient Care

    • All Clinics
    • Directions to SMOC
    • Subspecialties
  • Contact

    Contact

    • Administrative Staff
  • SUPPORT

Clinical Trials Unit

Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit. 

The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications.  The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments.  New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies. 

Skin Aging Studies

We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.

Nonmelanoma Skin Cancer

Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.

Acne Rosecea

This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.

Contact

For more information, please email dermtrials@stanford.edu

Featured Clinical Trials

The Myelin Disorders Biorepository Project

The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago.

Researchers working in the biorepository hope to use these materials to uncover new genetic etiologies for various leukodystrophies, develop biomarkers for use in future clinical trials, and better understand the natural history of these disorders. The knowledge gained from these efforts may help improve the diagnostic tools and treatment options available to patients in the future.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

  • Keith Van Haren, MD

Eligibility

Inclusion Criteria (Affected Subjects):

* Male or female of any age;
* Suspected or confirmed diagnosis of leukodystrophy or other disorder affecting the white matter of the brain based primarily on the finding of central nervous system neuroimaging consistent with this diagnosis or on an existing diagnosis of a leukodystrophy or genetic leukoencephalopathy as defined in existing classification systems;
* Documentation of informed consent by the subject, parent, or legal guardian, and, if appropriate, documentation of assent;
* Willingness to provide clinical data, participate in standardized assessments, and/or provide biologic samples.

Exclusion Criteria (Affected Subjects)

* Established diagnosis at the time of referral that is not consistent with a genetic disorder of the white matter, such as an acquired demyelinating condition (e.g. multiple sclerosis), or an infectious etiology, with the exception of sequelae of congenital infections such as CMV;
* Inability to provide consent.

Inclusion Criteria (Healthy Controls)

* Male or female of any age;
* Individuals with no confirmed or suspected diagnosis of leukodystrophy or other disorder affecting the white matter of the brain;
* Documentation of informed consent by the subject, parent, or legal guardian, and, if appropriate, documentation of assent.

Exclusion Criteria (Healthy Controls)

- Inability to provide consent.

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study

ALL

Now accepting new patients

  • Email this
  • View on clinicaltrials.gov

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Keith Van Haren, MD
Recruiting

Psoriasis Clinical Trials

The Myelin Disorders Biorepository Project

The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago.

Researchers working in the biorepository hope to use these materials to uncover new genetic etiologies for various leukodystrophies, develop biomarkers for use in future clinical trials, and better understand the natural history of these disorders. The knowledge gained from these efforts may help improve the diagnostic tools and treatment options available to patients in the future.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

  • Keith Van Haren, MD

Eligibility

Inclusion Criteria (Affected Subjects):

* Male or female of any age;
* Suspected or confirmed diagnosis of leukodystrophy or other disorder affecting the white matter of the brain based primarily on the finding of central nervous system neuroimaging consistent with this diagnosis or on an existing diagnosis of a leukodystrophy or genetic leukoencephalopathy as defined in existing classification systems;
* Documentation of informed consent by the subject, parent, or legal guardian, and, if appropriate, documentation of assent;
* Willingness to provide clinical data, participate in standardized assessments, and/or provide biologic samples.

Exclusion Criteria (Affected Subjects)

* Established diagnosis at the time of referral that is not consistent with a genetic disorder of the white matter, such as an acquired demyelinating condition (e.g. multiple sclerosis), or an infectious etiology, with the exception of sequelae of congenital infections such as CMV;
* Inability to provide consent.

Inclusion Criteria (Healthy Controls)

* Male or female of any age;
* Individuals with no confirmed or suspected diagnosis of leukodystrophy or other disorder affecting the white matter of the brain;
* Documentation of informed consent by the subject, parent, or legal guardian, and, if appropriate, documentation of assent.

Exclusion Criteria (Healthy Controls)

- Inability to provide consent.

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study

ALL

Now accepting new patients

  • Email this
  • View on clinicaltrials.gov

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Keith Van Haren, MD
Recruiting

Dermatology Clinical Trials

The Myelin Disorders Biorepository Project

The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago.

Researchers working in the biorepository hope to use these materials to uncover new genetic etiologies for various leukodystrophies, develop biomarkers for use in future clinical trials, and better understand the natural history of these disorders. The knowledge gained from these efforts may help improve the diagnostic tools and treatment options available to patients in the future.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

  • Keith Van Haren, MD

Eligibility

Inclusion Criteria (Affected Subjects):

* Male or female of any age;
* Suspected or confirmed diagnosis of leukodystrophy or other disorder affecting the white matter of the brain based primarily on the finding of central nervous system neuroimaging consistent with this diagnosis or on an existing diagnosis of a leukodystrophy or genetic leukoencephalopathy as defined in existing classification systems;
* Documentation of informed consent by the subject, parent, or legal guardian, and, if appropriate, documentation of assent;
* Willingness to provide clinical data, participate in standardized assessments, and/or provide biologic samples.

Exclusion Criteria (Affected Subjects)

* Established diagnosis at the time of referral that is not consistent with a genetic disorder of the white matter, such as an acquired demyelinating condition (e.g. multiple sclerosis), or an infectious etiology, with the exception of sequelae of congenital infections such as CMV;
* Inability to provide consent.

Inclusion Criteria (Healthy Controls)

* Male or female of any age;
* Individuals with no confirmed or suspected diagnosis of leukodystrophy or other disorder affecting the white matter of the brain;
* Documentation of informed consent by the subject, parent, or legal guardian, and, if appropriate, documentation of assent.

Exclusion Criteria (Healthy Controls)

- Inability to provide consent.

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study

ALL

Now accepting new patients

  • Email this
  • View on clinicaltrials.gov

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Keith Van Haren, MD
Recruiting

Pediatric Dermatology Clinical Trials

The Myelin Disorders Biorepository Project

The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago.

Researchers working in the biorepository hope to use these materials to uncover new genetic etiologies for various leukodystrophies, develop biomarkers for use in future clinical trials, and better understand the natural history of these disorders. The knowledge gained from these efforts may help improve the diagnostic tools and treatment options available to patients in the future.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

  • Keith Van Haren, MD

Eligibility

Inclusion Criteria (Affected Subjects):

* Male or female of any age;
* Suspected or confirmed diagnosis of leukodystrophy or other disorder affecting the white matter of the brain based primarily on the finding of central nervous system neuroimaging consistent with this diagnosis or on an existing diagnosis of a leukodystrophy or genetic leukoencephalopathy as defined in existing classification systems;
* Documentation of informed consent by the subject, parent, or legal guardian, and, if appropriate, documentation of assent;
* Willingness to provide clinical data, participate in standardized assessments, and/or provide biologic samples.

Exclusion Criteria (Affected Subjects)

* Established diagnosis at the time of referral that is not consistent with a genetic disorder of the white matter, such as an acquired demyelinating condition (e.g. multiple sclerosis), or an infectious etiology, with the exception of sequelae of congenital infections such as CMV;
* Inability to provide consent.

Inclusion Criteria (Healthy Controls)

* Male or female of any age;
* Individuals with no confirmed or suspected diagnosis of leukodystrophy or other disorder affecting the white matter of the brain;
* Documentation of informed consent by the subject, parent, or legal guardian, and, if appropriate, documentation of assent.

Exclusion Criteria (Healthy Controls)

- Inability to provide consent.

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study

ALL

Now accepting new patients

  • Email this
  • View on clinicaltrials.gov

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Keith Van Haren, MD
Recruiting

The Myelin Disorders Biorepository Project

The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago.

Researchers working in the biorepository hope to use these materials to uncover new genetic etiologies for various leukodystrophies, develop biomarkers for use in future clinical trials, and better understand the natural history of these disorders. The knowledge gained from these efforts may help improve the diagnostic tools and treatment options available to patients in the future.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

  • Keith Van Haren, MD

Eligibility

Inclusion Criteria (Affected Subjects):

* Male or female of any age;
* Suspected or confirmed diagnosis of leukodystrophy or other disorder affecting the white matter of the brain based primarily on the finding of central nervous system neuroimaging consistent with this diagnosis or on an existing diagnosis of a leukodystrophy or genetic leukoencephalopathy as defined in existing classification systems;
* Documentation of informed consent by the subject, parent, or legal guardian, and, if appropriate, documentation of assent;
* Willingness to provide clinical data, participate in standardized assessments, and/or provide biologic samples.

Exclusion Criteria (Affected Subjects)

* Established diagnosis at the time of referral that is not consistent with a genetic disorder of the white matter, such as an acquired demyelinating condition (e.g. multiple sclerosis), or an infectious etiology, with the exception of sequelae of congenital infections such as CMV;
* Inability to provide consent.

Inclusion Criteria (Healthy Controls)

* Male or female of any age;
* Individuals with no confirmed or suspected diagnosis of leukodystrophy or other disorder affecting the white matter of the brain;
* Documentation of informed consent by the subject, parent, or legal guardian, and, if appropriate, documentation of assent.

Exclusion Criteria (Healthy Controls)

- Inability to provide consent.

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study

ALL

Now accepting new patients

  • Email this
  • View on clinicaltrials.gov

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Keith Van Haren, MD
Recruiting

The Myelin Disorders Biorepository Project

The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago.

Researchers working in the biorepository hope to use these materials to uncover new genetic etiologies for various leukodystrophies, develop biomarkers for use in future clinical trials, and better understand the natural history of these disorders. The knowledge gained from these efforts may help improve the diagnostic tools and treatment options available to patients in the future.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

  • Keith Van Haren, MD

Eligibility

Inclusion Criteria (Affected Subjects):

* Male or female of any age;
* Suspected or confirmed diagnosis of leukodystrophy or other disorder affecting the white matter of the brain based primarily on the finding of central nervous system neuroimaging consistent with this diagnosis or on an existing diagnosis of a leukodystrophy or genetic leukoencephalopathy as defined in existing classification systems;
* Documentation of informed consent by the subject, parent, or legal guardian, and, if appropriate, documentation of assent;
* Willingness to provide clinical data, participate in standardized assessments, and/or provide biologic samples.

Exclusion Criteria (Affected Subjects)

* Established diagnosis at the time of referral that is not consistent with a genetic disorder of the white matter, such as an acquired demyelinating condition (e.g. multiple sclerosis), or an infectious etiology, with the exception of sequelae of congenital infections such as CMV;
* Inability to provide consent.

Inclusion Criteria (Healthy Controls)

* Male or female of any age;
* Individuals with no confirmed or suspected diagnosis of leukodystrophy or other disorder affecting the white matter of the brain;
* Documentation of informed consent by the subject, parent, or legal guardian, and, if appropriate, documentation of assent.

Exclusion Criteria (Healthy Controls)

- Inability to provide consent.

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study

ALL

Now accepting new patients

  • Email this
  • View on clinicaltrials.gov

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Keith Van Haren, MD
Recruiting

On this page

On this page

Ongoing & Upcoming Studies

Ongoing Studies

Upcoming Studies

Dermatology

Stanford Medicine

News

Careers

Contact

Health Care

Stanford Health Care

Stanford Children's Health

Stanford School of Medicine

About

Contact

Maps & Directions

Careers

Basic Science Departments

Clinical Science Departments

Academic Programs

Vision

Find People
Visit Stanford
Search Clinical Trials
Give a Gift
©2025 Stanford University
  • Privacy Policy
  • Terms of Use
  • Accessibility
  • See us on Facebook
  • See us on X (Twitter)
  • Stanford University
  • Stanford School of Medicine
  • Stanford Health Care
  • Stanford Children's Health
  • Stanford Health Care Tri-Valley
  • Stanford Medicine Partners